Microbio Co., Ltd. (4128)

Overview

Microbio Co., Ltd. is a Taiwanese enterprise focused on the research, development, manufacture, and trade of biotech drugs and dietary supplements. Since its inception in 2000, headquartered in Taipei, Taiwan, the company has embarked on a mission to contribute significantly to the pharmaceutical and healthcare industry. Microbio Co., Ltd. engages in a wide array of activities beyond its primary focus, including the trading of organic foods, sale of beverages, technology development, transfer and consultation services, publishing of magazines, and provision of business consulting services. Through its comprehensive range of products and services, Microbio aims to address numerous medical conditions and improve the quality of life for patients worldwide.

Products and Services

Microbio Co., Ltd. boasts a diverse portfolio ranging from clinical-stage drugs to dietary supplements, focusing on major diseases and conditions. Below is an outline of its key offerings:

• MS-20: A product developed to alleviate fatigue and appetite loss associated with cancer chemotherapy, providing support to cancer patients undergoing treatment.
• Herbiron: Targets the symptoms of iron deficiency anemia and menstrual discomfort, offering a non-prescription solution to common yet distressing conditions.
• Pre-Clinical Stage Products: Includes SNA-03 and SNA-07 for cancer immune therapy, SNP-630 for non-alcoholic steatohepatitis, FB918 for non-allergic eosinophilic asthma, and SNS812 for Cov-flu, highlighting the company’s efforts in expanding its research in critical healthcare needs.
• Phase I Clinical Trial Products: Features OB-318 for cancer, MB-110 for hepatitis C, SNP-810 as an acetaminophen alternative, FB317 for allergic asthma and chronic idiopathic urticaria, and FB704A for rheumatoid arthritis and other conditions, showcasing Microbio’s commitment to developing groundbreaking medical treatments.
• Phase II and III Clinical Trials: FB825 is in Phase II for atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy, while Phase III includes ON101 for diabetic foot ulcer and MB-6 as an adjuvant for metastatic colorectal cancer, progressing towards the marketplace to address unmet medical needs.
• Discovery Stage Pipeline: Focuses on FB121 for AIDS, SNA01 for PD-1 related cancer, SNA02 for cancer immune therapy, and SNS01 for recurrent metastatic non-small cell lung cancer, aiming at future solutions for critical health challenges.
• Additional Developments: The company is also working on SNP-830 and SNP-840 for creating a hepatotoxicity-free analgesic, expanding its portfolio into pain management without the common side-effects associated with such medication.

The diverse scope of Microbio Co., Ltd.’s product development emphasizes its role as a significant player in biotechnology, aiming to tackle various healthcare challenges with innovative solutions. The company’s broad-ranging endeavors from pre-clinical trials to discovery stage pipelines illustrate an ongoing commitment to research, development, and the provision of critical healthcare solutions.